Solara Active Pharma Sciences Reports Strong Q4'26 Results, Driven by Base Business Momentum

Solara Active Pharma Sciences Reports Strong Q4'26 Results, Driven by Base Business Momentum​

Solara Active Pharma Sciences Limited has reported its financial results for the quarter and year ended March 31, 2026. The company highlighted that its overall performance for Q4'26 reflected a sequential growth of 12% and a year-over-year (YoY) growth of 40%. Management noted that the company recorded its highest Revenue, Gross margin, and EBITDA in the last eight quarters.

The company attributes its positive momentum to its core Base business, which continues to demonstrate strong growth despite persistent headwinds in the commodity Ibuprofen segment.

Base Business Performance Drives Growth​

The Base business recorded a revenue growth of 24% Quarter-over-Quarter (QoQ) and 36% YoY. Furthermore, EBITDA grew 53% QoQ and 16% YoY. The margin profile of the Base business, at approximately 54% Gross Margin (GM) and 26% EBITDA, positioned the company among the leading API manufacturers in India.

For the Base business in Q4'26, the key financial highlights are as follows:


Looking at the full fiscal year, the Base business achieved:


Management stated that the Base business is building out its operations, successfully reducing exposure to commodity pricing volatility and global Ibuprofen oversupply. The Base business currently operates at approximately 75% of the total revenues, supported by a healthy product mix in regulated markets.

Commodity Ibuprofen Business Remains a Challenge​

In contrast, the Ibuprofen segment faced significant challenges. The business reported a revenue of INR 849 million in Q4'26, reflecting 17% QoQ growth but a 61% YoY increase compared to Q4'25. However, the segment's profitability remained weak.

The key metrics for the Ibuprofen business show the following declines:


For the fiscal year 2026, the Ibuprofen business recorded revenues of INR 3,336 million, with negative EBITDA of INR 527 million.

Given the persistent headwinds and weak profitability, the company announced that it has appointed bankers to evaluate strategic options for the Ibuprofen business, aiming to ensure optimal long-term value creation. Consequently, the carve out of the polymers and CRAMS business has been put on hold until strategic options for the Ibuprofen business are finalized in H1'27.

Overall Consolidated Results​

The overall performance for the company showed consolidated revenues of INR 3,919 million in Q4'26, marking a 12% QoQ growth and a 40% YoY increase. The overall business recorded a healthy Profit After Tax (PAT) of INR 96 million in Q4'26.

The financial performance over the last eight quarters saw the company record the highest Revenue, Gross margin, and EBITDA.

The overall financial performance comparison across the quarters and years is presented below:


On the balance sheet side, the company’s Net Debt was INR 7,719 million as of March 25, and it was reported at INR 6,141 million as of March 26. The company aims to reduce its Gross Debt through accelerated term loan repayment and improved internal accruals, anticipating an adjusted net debt of approximately INR 5,030 million by May'26.

SOLARA Stock Price Movement​

Solara Active Pharma Sciences Limited's shares edged higher today, closing at ₹579.95, representing a solid gain of 14.23%. The stock saw strong investor interest during the session, trading on a total volume of 2.97 million shares.